We use own cookies and thirds to offer you better service More information Accept
Back to News

Apr. 2018

New Ivabradine Qualigen


Qualigen launches Ivabradine to treat chronic stable angina pectoris and chronic heart failure

12 April 2018. Qualigen launches Ivabradina 5 mg and 7,5 mg film-coated tablets EFG.

Ivabradina Qualigen EFG is bioequivalent to Procolaran® and is indicated to treat chronic stable angina pectoris and chronic heart failure

Ivabradine Qualigen is marketed in presentations of 56 tablets of 5 mg and 7,5 mg.

Ivabradine Qualigen requires a prescription for dispensing and is financed by the Spanish Health System with reduced contribution.

With this launch, Qualigen extends its product portfolio of drugs for the heart failure.